(NASDAQ: LABP) Landos Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Landos Biopharma's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast LABP's revenue for 2027 to be $1,870,037, with the lowest LABP revenue forecast at $1,870,037, and the highest LABP revenue forecast at $1,870,037. On average, 1 Wall Street analysts forecast LABP's revenue for 2028 to be $56,724,468, with the lowest LABP revenue forecast at $56,724,468, and the highest LABP revenue forecast at $56,724,468.
In 2029, LABP is forecast to generate $304,816,096 in revenue, with the lowest revenue forecast at $304,816,096 and the highest revenue forecast at $304,816,096.